Your Health, We Care
Pacritinib is indicated for the treatment of adult patients with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis and a platelet count of less than 50 × 10⁹/L.
This indication was granted accelerated approval based on the reduction in spleen volume. Continued approval of this indication may be contingent upon the verification and description of its clinical benefit in confirmatory trials.
FDA，2025.10
